Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

War on the Nasdaq
Opinion

Simon Robertson: War on the Nasdaq

Who wins as Michael Burry declares war on AI?

Simon Robertson 08 Nov 2025
NZ sharemarket shakes off Wall Street fall to end firm
Markets

NZ sharemarket shakes off Wall Street fall to end firm

New Zealand shares shook off weakness in overseas markets.

Jamie Gray 07 Nov 2025
Seeka uncovers $350k fraud, sacks employee
Markets

Seeka uncovers $350k fraud, sacks employee

Three companies have been identified as being involved in the fraud, CEO says.

John Anthony 07 Nov 2025
Smyth to stay on as Spark chair for another year
Markets

Smyth to stay on as Spark chair for another year

The past year had been one of the toughest in Spark's history, chair says.

John Anthony 07 Nov 2025